Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) saw a large drop in short interest in the month of April. As of April 30th, there was short interest totaling 37,414 shares, a drop of 53.7% from the April 15th total of 80,782 shares. Currently, 1.5% of the company’s shares are sold short. Based on an average daily volume of 137,830 shares, the days-to-cover ratio is presently 0.3 days.

Hedge Funds Weigh In On Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC acquired a new stake in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision at the end of the most recent quarter. 20.34% of the stock is currently owned by hedge funds and other institutional investors.

Catheter Precision Trading Down 1.4%

NYSEAMERICAN:VTAK traded down $0.01 during trading hours on Friday, reaching $0.76. The company’s stock had a trading volume of 33,645 shares, compared to its average volume of 84,332. The firm has a market capitalization of $2.05 million, a price-to-earnings ratio of -0.04 and a beta of -1.04. The firm has a 50-day simple moving average of $1.08 and a 200-day simple moving average of $1.69. Catheter Precision has a 1 year low of $0.76 and a 1 year high of $15.68. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.08 and a current ratio of 0.10.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.